Drugs / Carvedilol
Carvedilol
also known as
COREG · carvedilol CR · COREG CR · Carvid · Dilatrend · carvedilol (Coreg) · Carvedilol Controlled Release (CR) · carvedilol slow-release (SR) · +4 more
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | COREG | — | 1997-05-29 – 2007-02-23 | fda.gov ↗ |
| Approved | US (FDA) | COREG | — | 1995-09-14 | fda.gov ↗ |
Trials 136 · started per year
today
US approved 1995
1
2
5
3
1
5
7
4
11
7
2
6
4
5
3
5
7
7
6
5
8
3
8
4
4
4
5
3
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT03980249 | Sep 2020 → Dec 2021 | glioblastoma | West Virginia University | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT03861598 | Jul 2019 → Aug 2020 | glioblastoma | West Virginia University | Terminated | No outcome recorded |
| Phase 0 | NCT03576664 | Aug 2018 → Sep 2019 | sleep-wake disorder | Gitte Moos Knudsen | Completed | No outcome recorded |
| Phase 119 trials · 2 met primary | ||||||
| Phase 1 | NCT04023110 | Aug 2019 → Aug 2024 | breast cancer, cardiomyopathy, chemotherapy-induced toxicity, heart failure | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02286934 | Sep → Nov 2014 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02120339 | May 2014 → Jun 2015 | pulmonary hypertension | University of Minnesota | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01793870 | Jan → Jun 2013 | cardiovascular-kidney-metabolic syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01568645 | Mar → Dec 2012 | pulmonary hypertension | National Heart, Lung, and Blood Institute (NHLBI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT01340248 | Jul → Aug 2011 | intermediate coronary syndrome | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT00742508 | Aug 2008 → Aug 2009 | congestive heart failure | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00557128 | Nov → Dec 2007 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00549510 | Oct → Dec 2007 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00537043 | Oct 2007 → Jan 2008 | essential hypertension | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00508365 | Sep 2007 → Jun 2008 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00240656 | Oct 2005 → May 2006 | pulmonary arterial hypertension | Hebei Medical University | Completed | No outcome recorded |
| Phase 1 | NCT00864149 | Oct → Nov 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864435 | Oct → Nov 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00648622 | Apr 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00650416 | Mar → Apr 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00834795 | Dec 2001 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00834873 | Dec 2001 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00004854 | — | heart disorder | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05194111 | Aug 2022 → Nov 2028 expected | heart failure | Virginia Commonwealth University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03361280 | Feb 2015 → Mar 2016 | chronic kidney disease | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 1/2 | NCT01723371 | Sep 2012 → Sep 2015 | pulmonary arterial hypertension | The Hospital for Sick Children | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00964678 | Jun 2010 → May 2014 | pulmonary arterial hypertension | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT00553969 | Nov 2007 → Sep 2010 | hypertensive disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 217 trials · 2 missed | ||||||
| Phase 2 | NCT07350070 | Dec 2025 → Jun 2027 expected | cirrhosis of liver, hepatocellular carcinoma, portal hypertension | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06844669 | Apr 2025 → Feb 2026 | HER2 positive breast carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT04977180 | Mar 2022 → Mar 2028 expected | acute myeloid leukemia | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT04218968 | Dec 2019 → Jun 2026 overdue | Parkinson disease, REM sleep behavior disorder | Cedars-Sinai Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03879629 | Aug 2019 → Feb 2026 | breast cancer | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03538015 | Apr 2019 → Aug 2020 | — | Owen Chan, PhD | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03775096 | Apr 2019 → Jul 2026 overdue | Parkinson disease, REM sleep behavior disorder | Michele Tagliati, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02944201 | Apr 2017 → Dec 2020 | prostate cancer | Montefiore Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02717507 | Apr 2016 → Jun 2022 | cancer, hematopoietic and lymphoid cell neoplasm | Children's Oncology Group | Completed | Missed primary |
| Phase 2 | NCT03867994 | Feb 2016 → May 2017 | — | rabab ahmed mohamed | Completed | No outcome recorded |
| Phase 2 | NCT02507011 | Jan 2016 → Jul 2019 | pulmonary arterial hypertension | University of Minnesota | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02993198 | Apr 2015 → Dec 2025 | HER2 positive breast carcinoma | Northwestern University | Unknown | Missed primary |
| Phase 2 | NCT02177175 | Jun 2014 → Jun 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01009918 | Mar 2010 → Aug 2017 | breast cancer, poisoning | University of South Florida | Completed | No outcome recorded |
| Phase 2 | NCT00442923 | Jul 2007 → Jun 2010 | anxiety, substance dependence | Aaron J. Janowsky | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00444834 | Apr → May 2007 | essential hypertension | Egalet Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT00000294 | Sep 1998 → Dec 2001 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04499898 | Oct 2018 → Dec 2030 expected | esophageal varices | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00524134 | Dec 2008 → Oct 2010 | epilepsy | Columbia University | Terminated | No outcome recorded |
| Phase 319 trials · 1 met primary · 4 missed | ||||||
| Phase 3 | NCT06263816 | Jun 2025 → Jul 2027 expected | cirrhosis of liver, portal hypertension | University Hospital, Tours | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04543643 | Nov 2021 → Oct 2023 | esophageal varices, hepatitis C induced liver cirrhosis | Tianjin Second People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04121299 | Jul 2021 → Jun 2026 | hypertensive disorder | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03542058 | Jun 2018 → Jun 2021 | cardiomyopathy due to anthracyclines | Makerere University | Unknown | No outcome recorded |
| Phase 3 | NCT03418961 | Nov 2017 → Sep 2027 expected | HER2 positive breast carcinoma, chemotherapy-induced toxicity, metastatic malignant neoplasm in the brain | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT02975323 | Dec 2014 → Jun 2017 | portal hypertension | Aga Khan University | Unknown | No outcome recorded |
| Phase 3 | NCT02012075 | Dec 2013 → Feb 2015 | heart failure | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01970059 | Oct 2013 | essential hypertension | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01756430 | Dec 2012 → Sep 2013 | essential hypertension | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01178528 | Sep 2009 → Jun 2010 | heart failure | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 3 | NCT01110824 | Apr 2008 → Dec 2011 | acute myeloid leukemia, plasma cell myeloma, precursor lymphoblastic lymphoma/leukemia | Hospital Clinic of Barcelona | Completed | Met primary |
| Phase 3 | NCT00624065 | Mar → Aug 2008 | essential hypertension | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00459056 | Apr 2007 → May 2010 | abdominal obesity-metabolic syndrome, hypertensive disorder | St. Paul Heart Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00347360 | Jul 2006 → Apr 2008 | hypertensive disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00273052 | Jan 2006 → Dec 2007 | hypertensive disorder | GlaxoSmithKline | Completed | Mixed |
| Phase 3 | NCT00272805 | Oct 2005 → Jul 2006 | heart failure | Cardiovascular Clinical Sciences Inc | Completed | Missed primary |
| Phase 3 | NCT00129363 | Jan 2002 → Jan 2006 | congestive heart failure | Shaddy, Robert, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT02832089 | Dec 2000 → Mar 2002 | atrial fibrillation | Andhra Medical College | Completed | No outcome recorded |
| Phase 3 | NCT00052026 | May 2000 → Jun 2005 | congestive heart failure | Shaddy, Robert, M.D. | Completed | Missed primary |
| Phase 445 trials · 4 met primary · 4 missed | ||||||
| Phase 4 | NCT06964464 | Aug 2025 → Jun 2031 expected | cardiomyopathy, sudden cardiac arrest, systolic heart failure | University of Rochester | Recruiting | No outcome recorded |
| Phase 4 | NCT06449339 | Jul 2024 → Jul 2031 expected | portal hypertension | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT06035978 | Mar 2024 → Apr 2026 | symptomatic heart failure | University Hospital Ostrava | Unknown | No outcome recorded |
| Phase 4 | NCT05585125 | Feb 2024 → Jul 2026 overdue | diastolic heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05019027 | Jan 2024 → Mar 2026 overdue | amyloidosis, heart disorder | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05637853 | Oct 2022 → Aug 2024 overdue | symptomatic heart failure | Göteborg University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05553314 | Nov 2021 → Jan 2026 | diastolic heart failure | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05179070 | Sep 2021 → Feb 2022 | heart failure | Universitas Sebelas Maret | Unknown | No outcome recorded |
| Phase 4 | NCT04939883 | Aug 2021 → May 2027 expected | cancer | Hospital Sirio-Libanes | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04769362 | May 2021 → Jan 2026 overdue | myocardial infarction | Samsung Medical Center | Recruiting | Met primary |
| Phase 4 | NCT03776955 | Jun 2019 → Sep 2024 | cirrhosis of liver, esophageal varices | King's College Hospital NHS Trust | Unknown | No outcome recorded |
| Phase 4 | NCT03948685 | May 2019 → Dec 2020 | diastolic heart failure | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT03778554 | Dec 2018 → Apr 2025 overdue | ST-elevation myocardial infarction | Bispebjerg Hospital | Active not recruiting | Met primary |
| Phase 4 | NCT03596385 | Oct 2018 → Jan 2025 | myocardial infarction | National Center for Cardiovascular Research Carlos III | Completed | Missed primary |
| Phase 4 | NCT03587558 | Sep 2017 → Dec 2019 | cardiac rhythm disease | Keimyung University Dongsan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT03169426 | May → Nov 2017 | myocardial infarction | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02251509 | Dec 2016 → Sep 2017 | atrial fibrillation | Creighton University | Unknown | No outcome recorded |
| Phase 4 | NCT02946892 | Nov 2016 → Dec 2019 | Fontan-associated liver disease, univentricular heart | University of Texas Southwestern Medical Center | Completed | Missed primary |
| Phase 4 | NCT03209180 | Oct 2016 → Jun 2018 | symptomatic heart failure | Seoul National University Bundang Hospital | Unknown | Met primary |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT02695732 | Dec 2015 → Sep 2018 | cirrhosis of liver, esophageal varices | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02385422 | Mar 2015 → Jun 2017 | cirrhosis of liver, esophageal varices, hemorrhagic disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02925975 | Jan 2015 → Jun 2020 | cirrhosis of liver, portal hypertension | Changqing Yang | Unknown | No outcome recorded |
| Phase 4 | NCT01656005 | Aug 2012 → Jul 2016 | chronic obstructive pulmonary disease | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT02504723 | Dec 2011 → Feb 2017 | esophageal varices | Kaohsiung Veterans General Hospital. | Completed | Missed primary |
| Phase 4 | NCT02547597 | Apr 2011 → Aug 2013 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01243827 | Nov 2010 → Dec 2012 | hypertensive disorder | Yoshio Matsui | Unknown | No outcome recorded |
| Phase 4 | NCT01059396 | Jan 2010 → Jul 2015 | esophageal varices, hepatic encephalopathy, infectious peritonitis, portal hypertension | Sant Pau Research Institute | Completed | Met primary |
| Phase 4 | NCT00819845 | Dec 2008 → Jun 2009 | Becker muscular dystrophy, Duchenne muscular dystrophy | Catholic University, Italy | Unknown | No outcome recorded |
| Phase 4 | NCT00732511 | Apr → Dec 2008 | diabetes mellitus, hypertensive disorder | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00669279 | Apr 2008 → Jul 2010 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00606775 | Dec 2007 → Dec 2008 | Duchenne muscular dystrophy, cardiomyopathy | Suzuka Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00402376 | Apr 2007 → ? | heart failure | University Hospital, Strasbourg, France | Terminated | No outcome recorded |
| Phase 4 | NCT00430040 | Feb 2007 → May 2013 | hypertensive disorder, type 2 diabetes mellitus | University at Buffalo | Terminated | No outcome recorded |
| Phase 4 | NCT00374465 | Jan 2006 → May 2008 | dilated cardiomyopathy | Medical University of Silesia | Unknown | No outcome recorded |
| Phase 4 | NCT00384566 | Jun 2005 → Apr 2008 | chronic obstructive pulmonary disease, heart failure | The Alfred | Withdrawn | No outcome recorded |
| Phase 4 | NCT00123604 | Jun 2004 → Jun 2006 | essential hypertension, type 2 diabetes mellitus | St. Paul Heart Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03370835 | Jun 2004 → Jun 2008 | asthma, chronic obstructive pulmonary disease | VA Greater Los Angeles Healthcare System | Completed | No outcome recorded |
| Phase 4 | NCT00497003 | Feb 2004 → Oct 2007 | — | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01557140 | May 2003 → Mar 2004 | Chagas cardiomyopathy, dilated cardiomyopathy, heart failure | Federal University of Minas Gerais | Completed | Missed primary |
| Phase 4 | NCT00344513 | Dec 2002 → Jun 2005 | congestive heart failure | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00381030 | Oct 2002 → Mar 2005 | congestive heart failure | Denver Health and Hospital Authority | Completed | No outcome recorded |
| Phase 4 | NCT01261065 | Dec 2001 → Oct 2005 | cardiomyopathy, heart failure | Michael E. DeBakey VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00060931 | Jun 2001 → Apr 2004 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00060918 | Jun 2001 → Apr 2004 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable26 trials · 3 met primary · 1 missed | ||||||
| — | NCT07587671 | Aug 2026 → Mar 2029 expected | cirrhosis of liver, esophageal varices with bleeding, hepatic encephalopathy, portal hypertension | West China Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07577518 | Jun 2026 → Apr 2030 expected | coronary artery disorder | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07465471 | Mar 2026 → Sep 2027 expected | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT06861075 | Apr 2025 → Mar 2028 expected | cirrhosis of liver, portal hypertension | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| — | NCT05699824 | Jul 2023 → Jun 2024 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT06015373 | Jun 2023 | portal hypertension | Centro Hospitalar De São João, E.P.E. | Completed | No outcome recorded |
| — | NCT05767229 | Mar 2023 → Nov 2024 | portal hypertension | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT05651789 | Jan 2023 → Dec 2024 | cirrhosis of liver, portal hypertension, varicose disease | West China Hospital | Unknown | No outcome recorded |
| — | NCT05180292 | Jan 2022 → Dec 2024 | liver failure | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT05057572 | Oct 2021 → Dec 2023 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | Met primary |
| — | NCT05021406 | Jan 2021 → Oct 2024 | cirrhosis of liver, portal hypertension | Beijing Friendship Hospital | Unknown | No outcome recorded |
| — | NCT04111133 | Jan 2020 → Oct 2024 | cirrhosis of liver, cirrhotic cardiomyopathy, portal hypertension | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| — | NCT04221919 | Jan 2020 → Jan 2021 | strictly posterior acute myocardial infarction | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| — | NCT03736265 | Oct 2017 → Nov 2022 | cirrhosis of liver, portal hypertension | Beijing Friendship Hospital | Unknown | Missed primary |
| — | NCT03069339 | Mar 2017 → Nov 2020 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | Met primary |
| — | NCT02583698 | Oct 2015 → Jul 2017 | liver failure | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT02357004 | Feb 2015 → Jan 2020 | hypertensive disorder | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| — | NCT02294292 | Jul 2014 → Aug 2016 | diastolic heart failure, liver disorder | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01196481 | Dec 2012 → Aug 2015 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01270672 | Jan → May 2011 | mood disorder, substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT01196507 | Nov 2010 → Apr 2014 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | Met primary |
| — | NCT01212250 | Sep 2010 → Dec 2026 expected | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Recruiting | No outcome recorded |
| — | NCT02406586 | Jul 2009 → Mar 2011 | diabetes mellitus, hypertensive disorder | Emory University | Completed | No outcome recorded |
| — | NCT00578617 | Sep 2006 → Feb 2009 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00214318 | Jan 2005 → Feb 2007 | heart failure | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00198614 | Jan 2005 → ? | atrial fibrillation, coronary artery disorder | Ministry of Health, Labour and Welfare, Japan | Completed | No outcome recorded |
| Comparator or background therapy86 trials | ||||||
| Phase 0 | NCT06108518 Comparator | Jun → Oct 2024 | rheumatoid arthritis | Tanta University | Unknown | No outcome recorded |
| Phase 0 | NCT06643221 Comparator | Jan 2018 → May 2031 expected | leukemia, lymphoma | University of Arizona | Recruiting | No outcome recorded |
| Phase 1 | NCT06304896 Comparator | May 2024 → May 2025 | chemotherapy-induced toxicity | Arab Contractors Medical Centre | Unknown | No outcome recorded |
| Phase 1 | NCT02907021 Background | Nov 2016 → Apr 2018 | breast cancer, heart failure | Population Health Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT06836856 Comparator | Jan → Jun 2025 overdue | traumatic brain injury | Mansoura University | Recruiting | No outcome recorded |
| Phase 2 | NCT04190433 Background | Sep 2020 → Apr 2023 | breast carcinoma, lymphoma, sarcoma | Mayo Clinic | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02230891 Comparator | Oct 2014 → Dec 2020 | diabetes mellitus, hypertensive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01221792 Comparator | Oct 2010 → Jun 2011 | post-traumatic stress disorder | Columbia Northwest Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT01171183 Comparator | Aug 2010 → May 2014 | cocaine dependence, substance withdrawal syndrome | University of Arkansas | Completed | No outcome recorded |
| Phase 2/3 | NCT06696248 Background | Nov 2024 → Sep 2025 overdue | portal hypertension | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06470386 Comparator | Jun 2024 → Nov 2025 | portal hypertension | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03720067 Comparator | Jan 2019 → Dec 2020 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | Federal University of Rio de Janeiro | Unknown | No outcome recorded |
| Phase 3 | NCT05931276 Comparator | May 2024 → Dec 2026 expected | end stage renal failure | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 3 | NCT06853951 Comparator | Jul 2023 → Mar 2025 overdue | chemotherapy-induced toxicity | Ain Shams University | Recruiting | No outcome recorded |
| Phase 3 | NCT05849766 Comparator | Apr 2023 → May 2024 | dilated cardiomyopathy | October 6 University | Completed | No outcome recorded |
| Phase 3 | NCT04345796 Comparator | Feb 2021 → Jun 2024 | tricuspid valve insufficiency | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02066649 Comparator | Jul 2018 → Mar 2019 | portal hypertension | Rutgers, The State University of New Jersey | Withdrawn | No outcome recorded |
| Phase 3 | NCT01724450 Comparator | Apr 2013 → Jun 2017 | breast cancer, chemotherapy-induced toxicity, heart failure | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT01413048 Comparator | Jan 2011 → Mar 2012 | essential hypertension | Ahn-Gook Pharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT00657241 Comparator | Apr 2008 → Apr 2010 | hypertensive disorder | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT00589303 Comparator | Dec 2007 → Jul 2011 | atrial fibrillation, heart failure | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00313157 Comparator | Apr 2006 → Sep 2010 | atrial fibrillation | Asker & Baerum Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00323037 Comparator | Mar 2006 → Apr 2008 | congestive heart failure | CTI-1, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00493480 Comparator | Sep 2003 → Aug 2009 | cirrhosis of liver, portal hypertension | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 4 | NCT07521332 Background | Apr 2026 → Apr 2027 expected | cirrhosis of liver, esophageal varices, hepatic encephalopathy, portal hypertension +1 | Asian Institute Of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT07322237 Comparator | Apr 2026 → Jan 2029 expected | cardiovascular-kidney-metabolic syndrome, cirrhosis of liver, cirrhotic cardiomyopathy | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 4 | NCT07513883 Background | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT07103655 Background | Mar → Nov 2026 expected | hypertrophic cardiomyopathy | Second Affiliated Hospital, Zhejiang University, School of Medicine | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07298993 Comparator | Feb 2026 → Apr 2029 expected | heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07352228 Comparator | Jan → Sep 2026 overdue | portal hypertension | Xijing Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07238452 Comparator | Dec 2025 → Dec 2032 expected | atrial fibrillation, symptomatic heart failure | University of British Columbia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06594783 Comparator | Jan 2025 → Oct 2030 expected | cirrhosis of liver, esophageal varices | Taipei Veterans General Hospital, Taiwan | Recruiting | No outcome recorded |
| Phase 4 | NCT06594744 Comparator | Oct 2024 → Oct 2030 expected | esophageal varices, hepatocellular carcinoma | Taipei Veterans General Hospital, Taiwan | Recruiting | No outcome recorded |
| Phase 4 | NCT07397481 Comparator | Mar 2024 → Mar 2025 | cirrhosis of liver, hypertensive disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT04757584 Comparator | Apr 2021 → Apr 2023 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04767061 Comparator | Apr 2021 → Apr 2022 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04575675 Background | May → Nov 2020 | heart failure, hypotensive disorder | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04049786 Comparator | Jun 2019 → Aug 2022 | obesity disorder | Natalia Valadares de Moraes | Unknown | No outcome recorded |
| Phase 4 | NCT05872698 Comparator | Apr 2019 → Dec 2026 expected | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | King's College Hospital NHS Trust | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03646357 Comparator | Oct 2018 → Apr 2025 overdue | ST-elevation myocardial infarction | Oslo University Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02945982 Background | Apr 2018 → Jun 2020 | portal hypertension | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02907749 Background | Jan 2018 → Jan 2020 | cirrhosis of liver, portal hypertension | Changqing Yang | Completed | No outcome recorded |
| Phase 4 | NCT02809820 Comparator | May → Dec 2016 | acute coronary syndrome | Federico II University | Completed | No outcome recorded |
| Phase 4 | NCT02638415 Background | Dec 2015 → Jun 2018 | cirrhosis of liver, esophageal varices | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT01774656 Background | Jan 2013 → Dec 2017 | advanced heart failure | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT01383044 Comparator | Jul 2011 → Jul 2015 | esophageal varices with bleeding | E-DA Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01354444 Comparator | Jun 2011 → Dec 2016 | Alzheimer disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT02056626 Comparator | Mar 2011 → Nov 2018 | hypertensive disorder | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT01425164 Comparator | Jan 2011 → Jun 2012 | coronary artery disorder | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT01155635 Comparator | Jul 2010 → Jun 2015 | myocardial infarction | Takeshi Morimoto | Completed | No outcome recorded |
| Phase 4 | NCT00827775 Comparator | Jun 2009 → Sep 2010 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00673075 Comparator | May 2008 → Sep 2009 | coronary artery disorder, hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00496834 Comparator | Feb 2008 → Sep 2009 | hypertensive disorder | Organon and Co | Completed | Missed primary |
| Phase 4 | NCT00517725 Comparator | Jul 2007 → May 2010 | congestive heart failure | Centro Cardiologico Monzino | Completed | No outcome recorded |
| Phase 4 | NCT00433043 Comparator | Jan 2007 → May 2009 | congestive heart failure | St. Luke's-Roosevelt Hospital Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00924833 Comparator | May → Nov 2006 | altitude sickness, heart failure | Istituto Auxologico Italiano | Completed | No outcome recorded |
| Phase 4 | NCT01103154 Comparator | Mar 2005 → Jan 2010 | esophageal varices with bleeding | E-DA Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00642434 Comparator | Jan 2004 → Jun 2008 | type 2 diabetes mellitus | University of New Mexico | Completed | No outcome recorded |
| Phase 4 | NCT01070641 Comparator | Jun 2002 → Feb 2011 | portal hypertension | Aga Khan University | Unknown | No outcome recorded |
| Phase 4 | NCT01798992 Comparator | Sep 2000 → Mar 2009 | non-familial dilated cardiomyopathy | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT06930092 Comparator | Aug 2025 → Apr 2028 expected | cardiomyopathy | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT07111221 Background | Jun 2025 → Oct 2029 expected | cirrhosis of liver, portal hypertension | Medical University of Warsaw | Recruiting | No outcome recorded |
| — | NCT07108075 Background | Jun → Oct 2025 overdue | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Recruiting | No outcome recorded |
| — | NCT06431919 Background | Jun 2025 → Jan 2028 expected | acute kidney injury, cirrhosis of liver, cirrhotic cardiomyopathy, diastolic heart failure | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| — | NCT06836778 Background | Feb 2025 → Jan 2026 overdue | hepatocellular carcinoma | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT06566794 Comparator | Aug 2024 → Jan 2025 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT06041932 Background | Nov 2023 → Aug 2024 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT05553717 Comparator | Oct 2022 → Oct 2023 | esophageal ulcer, myocardial ischemia | Tanta University | Unknown | No outcome recorded |
| — | NCT04254822 Background | Jun 2020 → Dec 2023 | cirrhosis of liver, esophageal varices with bleeding | Air Force Military Medical University, China | Unknown | No outcome recorded |
| — | NCT02619526 Comparator | Dec 2016 → Jul 2018 | heart failure | Dong-A University | Unknown | No outcome recorded |
| — | NCT01659346 Comparator | Feb 2016 → Dec 2017 | hepatocellular carcinoma | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
| — | NCT02465645 Comparator | Jun 2015 → Jan 2017 | esophageal varices | Institute of Liver and Biliary Sciences, India | Completed | Missed primary |
| — | NCT02137733 Comparator | Jun 2013 → May 2016 | heart failure | Mebix Inc | Unknown | No outcome recorded |
| — | NCT01586156 Comparator | Dec 2012 → Jul 2016 | pulmonary hypertension | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT01608893 Comparator | May 2012 → Jun 2025 | atrial fibrillation | University of Calgary | Unknown | No outcome recorded |
| — | NCT00911508 Comparator | Nov 2009 → Dec 2017 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00878384 Comparator | Apr 2009 → Jun 2012 | atrial fibrillation, heart failure | Royal Brompton & Harefield NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT00566969 Comparator | Sep 2007 → Dec 2012 | cocaine dependence, opiate dependence | Yale University | Completed | No outcome recorded |
| — | NCT00292162 Comparator | Jan 2007 → Jul 2009 | atrial fibrillation, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2017-12-08 | Impax Laboratories, LLC | Regulatory Impax Receives Tentative FDA Approval of Generic Coreg CR® (Carvedilol Phosphate) Extended-Release Capsules amneal.com ↗
today announced it has received tentative U.S. Food and Drug Administration (" FDA ") approval on its Abbreviated New Drug Application ("ANDA") for a generic version of Coreg CR ® (carvedilol phosphate) extended-release capsules, 10, 20, 40 and 80 mg. |
| 2017-10-26 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces US FDA approval for generic Coreg CR® sunpharma.com ↗ |
| 2007-09-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval And Shipment Of Generic Coreg® Tablets tevapharm.com ↗
the U.S. Food and Drug Administration (FDA) has granted final approval for the company's Abbreviated New Drug Application (ANDA) to market its Generic version of GlaxoSmithKline's cardiovascular agent Coreg® (Carvedilol) Tablets |
| 2004-06-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval Of Carvedilol Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Carvedilol Tablets, 3.125 mg, 6.25 mg, 12.5 mg and 25 mg. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-12-08 | Impax Laboratories, LLC | Impax Receives Tentative FDA Approval of Generic Coreg CR® (Carvedilol Phosphate) Extended-Release Capsules amneal.com ↗ |
| 2017-10-26 | Sun Pharmaceutical Industries, Inc. | Sun Pharma announces US FDA approval for generic Coreg CR® sunpharma.com ↗ |
| 2015-05-08 | InnoPharmax Inc. | InnoPharmax Selected for Poster Presentation on "Carvedilol" and "Oral Insulin" at 2015 CRS Annual Meeting innopharmax.com ↗ |
| 2007-09-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval And Shipment Of Generic Coreg® Tablets tevapharm.com ↗ |
| 2004-06-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Carvedilol Tablets tevapharm.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 225 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carvedilol | “The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ...” NCT01774656 ↗217“The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing...” NCT00442923 ↗ “Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol...” PMID 39645270 ↗ Aug 2024 “Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “including the beta-blocker, carvedilol, and the ACE-I, ramipril, as tolerated, at the maximum doses tolerated, up to carvedilol 25mg BID and ramipril 10mg once daily” NCT02907021 ↗ “All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion.” NCT05637853 ↗ “Carvedilol will be the preferred nonselective beta-blocker, starting at 6.25 mg once daily and increasing to 12.5 mg once daily after 1 week if tolerated.” NCT07587671 ↗ “Significant reduction of portal pressure is observed in up to 50% of patients treated with propranolol and up to 75% with carvedilol.” NCT07111221 ↗ “Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis.” PMID 31305281 ↗ Jul 2020 “The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate.” NCT07298993 ↗ |
| Known as | carvedilol (Coreg) | “carvedilol (Coreg)” NCT00000620 ↗ |
| Known as | Carvedilol Controlled Release (CR) | “Drug: Carvedilol Controlled Release (CR)” NCT00430040 ↗ |
| Known as | carvedilol CR | “Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at...” NCT00430040 ↗3“Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.” NCT00524134 ↗ “once-daily extended-release carvedilol (carvedilol CR) combined with the ACEI lisinopril” PMID 20883227 ↗ Jul 2010 “Drug: Carvedilol CR” NCT00657241 ↗ |
| Known as | carvedilol slow-release (SR) | “carvedilol slow-release (SR)” NCT05553314 ↗ |
| Known as | carvedilol-SR | “The objective of this trial is to evaluate the effect of sustained-release carvedilol (carvedilol-SR) on the outcome [N-terminal pro-B-natriuretic peptide (NT-proBNP)...” PMID 38737708 ↗ Apr 2024 |
| Known as | Carvid | “Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®” NCT05849766 ↗1“Carvid (carvedilol)” NCT06836856 ↗ |
| Known as | COREG | “The objective of this study was to investigate the bioequivalence of Mylan's carvedilol 12.5 mg tablets to GSK's Coreg® 12.5 mg tablets following a single, oral 12.5 mg (1 x...” NCT00650416 ↗7“The objective of this study was to investigate the bioequivalence of Mylan's carvedilol 12.5 mg tablets to GSK's Coreg® 12.5 mg tablets following a single, oral 12.5 mg (1 x...” NCT00648622 ↗ “The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release...” NCT00272805 ↗ “Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in...” NCT05872698 ↗ “The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.” NCT00508365 ↗ “mortality benefits (carvedilol \[Coreg\] 25 mg bid, metoprolol succinate \[Toprol-XL\] 200 mg qd)” NCT00433043 ↗ “commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals)” NCT00834873 ↗ “commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals)” NCT00834795 ↗ |
| Known as | COREG CR | “20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR)” NCT00347360 ↗ |
| Known as | CVD | “CECCY trial demonstrated that the β-blocker carvedilol (CVD) could attenuate myocardial injury secondary to ANT.” PMID 35087624 ↗ Jan 2022 |
| Known as | Dilatrend | “Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗ |
| Known as | Dilatrend SR | “Carvedilol SR (Dilatrend SR; 8/16/32/64 mg) once daily, starting at 32 mg and up-titrated to maximal tolerated dose (up to 128 mg).” NCT07577518 ↗ |
| Known as | Dilatrend Tab | “Dilatrend Tab® (carvedilol) 12.5 mg” NCT00496834 ↗ |
| Action | Inhibit | “blockage of adrenergic receptors by carvedilol” NCT00000294 ↗ |
| Modality | Other / unclassified | “Carvedilol and bisoprolol are established beta-blockers for treating hypertension or chronic heart failure” NCT01243827 ↗ |
| Route | Oral | “a single oral dose of low (25mg) or high dose of carvedilol (50mg)” NCT00000294 ↗ |